<DOC>
	<DOCNO>NCT02453867</DOCNO>
	<brief_summary>Study purpose To establish efficacy safety reduce immunosuppressive therapy tacrolimus daily senior ( &gt; 65 year age ) renal transplant recipient</brief_summary>
	<brief_title>Efficacy Safety Reduced Immunosuppression vs. Standard Triple Therapy Senior Renal Transplant Recipients</brief_title>
	<detailed_description>Study outline Stable senior transplant recipient ( &gt; 65 year age ) participate European SENIOR transplant registry may enter trial month 3 post-transplant , fulfil in- none exclusion criterion . At time patient randomize 1:1 either continue Reference therapy : Tacrolimus daily ( Advagraf® ) Mycophenolate ( either MMF ≥1g/d EC-MPS ≥720g/d ) Steroids ( ≥5mg prednisolone equivalent ) Investigational therapy : Tacrolimus daily ( Advagraf® ) Steroid stop month 3 ( taper within 2 week ) Mycophenolate stop month 6</detailed_description>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>1 . Males female , age ≥65 year participate European SENIOR transplant registry 2 . Patients receive renal allograft 3 3.5 month prior randomization . 3 . Patient must receive primary secondary renal allograft blood group compatible donor 4 . Standard criterion donor ( SCD ) , expand criterion donor ( ECD ) , donor cardiac death ( DCD ) living donor ( LD ) eligible 5 . Patients willing able participate study write informed consent obtain 6 . Patients continuous standard triple therapy tacrolimus daily ( Advagraf , trough level ≥5ng/ml ) combination mycophenolate ( either ≥1.0g/day MMF ≥720mg/d ECMPS ) steroid ( ≥5mg prednisolone equivalent ) since transplantation 7 . Stable graft function serum creatinine ≤2.5 mg/dl . 8 . Patients low standard immunological risk , PRA 20 % know donor specific antibody ( DSA ) transplantation 1 . Patient mental dysfunction inability comply study protocol 2 . Patients , accord investigator require medical reason ( e.g . previous rejection ) continuous triple therapy different tacrolimus exposure 3 . Multiorgan recipient ( solid organ ( e.g . pancreas ) bone marrow ) 4 . Blood group ABOincompatible allografts 5 . Patients suffer severe Tcell mediate rejection ( Banff II acute rejection ) , recurrent acute rejection ( &gt; 1 episode ) , steroid resistant rejection posttransplant 6 . History antibodymediated rejection ( acute chronic ) 7 . History rejection 2 month prior inclusion 8 . Documented presence donor specific antibody ( DSA ) accord local lab result baseline 9 . Panel reactive antibody ( PRA ) &gt; 20 % prior transplantation , measure accord local standard 10 . Patients receive receive Sirolimus , Everolimus , Azathioprine , Belatacept Cyclophosphamide within 3 month prior enrolment 11 . Patients receive induction therapy Basiliximab ( e.g . deplete polyclonal antithymocyte antibody ( ATG ) , OKT3 , Alemtuzumab ) 12 . Patients proteinuria &gt; 1.0 g/day ( &gt; 1.0 g/g creatinine ) screening experienced nephrotic syndrome due recurrence focal segmental glomerulosclerosis ( FSGS ) 13 . History alcohol drug abuse le 6 month sobriety 14 . Patient known hereditary immunodeficiency 15 . Patient active malignancy posttransplant exception local , noninvasive , fully excise , cutaneous basal cell carcinoma , cutaneous squamous cell carcinoma , cervical carcinoma situ 16 . Patients clinically symptomatic congestive heart failure symptomatic coronary artery disease 17 . Patients document ( either serology and/or nuclear acid testing ( NAT ) clinically active infection ( e.g . know Hepatitis B , Hepatitis C , HIV , CMV BK virus infection ) 18 . Participation investigational clinical trial 3 month participation study , except SENIOR transplant registry 19 . Patients leukopenia ( &lt; 2500 cells/nl ) neutropenia ( &lt; 1500 cells/nl ) 20 . Patients thrombocytopenia ( &lt; 100 cells/nl ) 21 . Patients liver transaminase bilirubin value &gt; 3x normal value 22 . Any significant disease clinically significant finding , include psychiatric behavioural problem , medical history and/or physical examination finding would opinion investigator preclude patient participate study . 23 . Patients institutionalized official court order</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>kidney transplantation</keyword>
	<keyword>senior kidney transplant recipient</keyword>
	<keyword>tacrolimus daily</keyword>
	<keyword>reduce immunosuppression</keyword>
	<keyword>recipient &gt; 65 year</keyword>
	<keyword>Senior</keyword>
</DOC>